DNX Biopharmaceuticals, Inc.

DNX Biopharmaceuticals, Inc. is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of lifelong diseases. Founded in 2014 and headquartered in Irvine, California, USA, DNX is committed to leveraging 21st-century half-life extension platform technology, PASylation, to develop new therapeutic proteins. This technology has been licensed from XL-protein GmbH. XLp grants DNX a global exclusive license based on patents and proprietary knowledge related to PASylation technology to develop and commercialize a variety of PASylated products.